LONDON: Strong sales of some of GlaxoSmithKline plc’s (GSK) newest drugs have led to 17% growth in its first-quarter net income, despite generic competition to its former best-seller, the pharmaceutical group reported.
For the three months to March 31, GSK posted earnings of £1.19bil, compared with £1.02bil in the same quarter last year. Sales, of which most came from the United States, totalled £5.22bil, up 2% on £5.11bil a year ago.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!